Answers are grounded in this paper and cite their sources.
Background: Guyana, located on the northern South American Mainland is a moderate resource, developing country with high rates of traumatic hemorrhage. There is a shortage of blood products available for use in the emergency department of Georgetown Public Hospital, the main tertiary public hospital. Tranexamic acid (TXA) is an antifibrinolytic that inhibits both plasminogen activation and plasmin activity, thus preventing clot breakdown. CRASH-2, a large randomized, multicenter double blind, placebo-controlled clinical trial, that showed that TXA reduces mortality and blood product use in acute trauma in a moderate resource setting. Currently TXA is not available for use in the public health system in Guyana.
No takes yet. Share an insight, caveat, or question.
Hemchand Jhagru (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: